Logo image of IMMX

IMMIX BIOPHARMA INC (IMMX) Stock Price, Quote, News and Overview

NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD

2.095  +0.06 (+2.7%)

IMMX Quote, Performance and Key Statistics

IMMIX BIOPHARMA INC

NASDAQ:IMMX (5/2/2025, 8:02:14 PM)

2.095

+0.06 (+2.7%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.71
52 Week Low1.26
Market Cap58.07M
Shares27.72M
Float16.64M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07
IPO12-16 2021-12-16


IMMX short term performance overview.The bars show the price performance of IMMX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

IMMX long term performance overview.The bars show the price performance of IMMX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -5 -10

The current stock price of IMMX is 2.095 USD. In the past month the price increased by 32.59%. In the past year, price decreased by -10.85%.

IMMIX BIOPHARMA INC / IMMX Daily stock chart

IMMX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About IMMX

Company Profile

IMMX logo image Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Company Info

IMMIX BIOPHARMA INC

11400 West Olympic Blvd., Suite 200

Los Angeles CALIFORNIA US

Employees: 16

IMMX Company Website

IMMX Investor Relations

Phone: 18889581084

IMMIX BIOPHARMA INC / IMMX FAQ

What is the stock price of IMMIX BIOPHARMA INC today?

The current stock price of IMMX is 2.095 USD. The price increased by 2.7% in the last trading session.


What is the ticker symbol for IMMIX BIOPHARMA INC stock?

The exchange symbol of IMMIX BIOPHARMA INC is IMMX and it is listed on the Nasdaq exchange.


On which exchange is IMMX stock listed?

IMMX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IMMIX BIOPHARMA INC stock?

7 analysts have analysed IMMX and the average price target is 7.14 USD. This implies a price increase of 240.81% is expected in the next year compared to the current price of 2.095. Check the IMMIX BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IMMIX BIOPHARMA INC worth?

IMMIX BIOPHARMA INC (IMMX) has a market capitalization of 58.07M USD. This makes IMMX a Micro Cap stock.


How many employees does IMMIX BIOPHARMA INC have?

IMMIX BIOPHARMA INC (IMMX) currently has 16 employees.


What are the support and resistance levels for IMMIX BIOPHARMA INC (IMMX) stock?

IMMIX BIOPHARMA INC (IMMX) has a support level at 1.34 and a resistance level at 2.1. Check the full technical report for a detailed analysis of IMMX support and resistance levels.


Should I buy IMMIX BIOPHARMA INC (IMMX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IMMIX BIOPHARMA INC (IMMX) stock pay dividends?

IMMX does not pay a dividend.


When does IMMIX BIOPHARMA INC (IMMX) report earnings?

IMMIX BIOPHARMA INC (IMMX) will report earnings on 2025-05-07.


What is the Price/Earnings (PE) ratio of IMMIX BIOPHARMA INC (IMMX)?

IMMIX BIOPHARMA INC (IMMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).


What is the Short Interest ratio of IMMIX BIOPHARMA INC (IMMX) stock?

The outstanding short interest for IMMIX BIOPHARMA INC (IMMX) is 1.15% of its float. Check the ownership tab for more information on the IMMX short interest.


IMMX Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to IMMX. When comparing the yearly performance of all stocks, IMMX turns out to be only a medium performer in the overall market: it outperformed 49.72% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IMMX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IMMX. The financial health of IMMX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMMX Financial Highlights

Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 11.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -94.18%
ROE -163.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%30.43%
Sales Q2Q%N/A
EPS 1Y (TTM)11.42%
Revenue 1Y (TTM)N/A

IMMX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to IMMX. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners12.26%
Ins Owners28.49%
Short Float %1.15%
Short Ratio3.78
Analysts
Analysts82.86
Price Target7.14 (240.81%)
EPS Next Y14.46%
Revenue Next YearN/A